Cargando…
Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial
BACKGROUND: There are limited data on uninterrupted anticoagulation with direct oral anticoagulants during catheter ablation for atrial fibrillation (AF), particularly in Japan. We planned a subgroup analysis of the RE‐CIRCUIT study, comparing the use of uninterrupted dabigatran therapy with warfari...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891433/ https://www.ncbi.nlm.nih.gov/pubmed/29657590 http://dx.doi.org/10.1002/joa3.12024 |
_version_ | 1783313005276037120 |
---|---|
author | Yoshida, Yukihiko Watarai, Masato Fujii, Kenshi Shimizu, Wataru Satomi, Kazuhiro Inden, Yasuya Murakami, Yoshimasa Murakami, Masato Iwasa, Atsushi Kimura, Masaomi Yamada, Nobuko Nakagawa, Tomofumi Nordaby, Matias Okumura, Ken |
author_facet | Yoshida, Yukihiko Watarai, Masato Fujii, Kenshi Shimizu, Wataru Satomi, Kazuhiro Inden, Yasuya Murakami, Yoshimasa Murakami, Masato Iwasa, Atsushi Kimura, Masaomi Yamada, Nobuko Nakagawa, Tomofumi Nordaby, Matias Okumura, Ken |
author_sort | Yoshida, Yukihiko |
collection | PubMed |
description | BACKGROUND: There are limited data on uninterrupted anticoagulation with direct oral anticoagulants during catheter ablation for atrial fibrillation (AF), particularly in Japan. We planned a subgroup analysis of the RE‐CIRCUIT study, comparing the use of uninterrupted dabigatran therapy with warfarin therapy during catheter ablation among the Japanese subgroup and with that in the total population. METHODS: The RE‐CIRCUIT study utilized a prospective, randomized, open‐label, blinded endpoint design, and the primary endpoint was the incidence of major bleeding events (MBEs). Patients were randomized to uninterrupted dabigatran 150 mg twice daily or warfarin. In this study, we analyzed the results in Japanese patients. RESULTS: Of 704 enrolled patients in the study, 112 Japanese patients were randomized to dabigatran (n = 65) or warfarin (n = 47). MBEs were experienced by two patients: one in the dabigatran group (1.6%, cardiac tamponade) and one in the warfarin group (2.2%, groin hematoma) (risk difference vs warfarin −0.6%; 95% CI −5.8, 4.7). Within the Japanese subgroup, there were no thromboembolic events in both groups. CONCLUSION: While not designed to show statistical difference between two treatment groups, our results from the Japanese subgroup supported those from the overall population. Furthermore, this study provided clinical information regarding MBE, especially cardiac tamponade, in Japanese patients. |
format | Online Article Text |
id | pubmed-5891433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58914332018-04-13 Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial Yoshida, Yukihiko Watarai, Masato Fujii, Kenshi Shimizu, Wataru Satomi, Kazuhiro Inden, Yasuya Murakami, Yoshimasa Murakami, Masato Iwasa, Atsushi Kimura, Masaomi Yamada, Nobuko Nakagawa, Tomofumi Nordaby, Matias Okumura, Ken J Arrhythm Original Articles BACKGROUND: There are limited data on uninterrupted anticoagulation with direct oral anticoagulants during catheter ablation for atrial fibrillation (AF), particularly in Japan. We planned a subgroup analysis of the RE‐CIRCUIT study, comparing the use of uninterrupted dabigatran therapy with warfarin therapy during catheter ablation among the Japanese subgroup and with that in the total population. METHODS: The RE‐CIRCUIT study utilized a prospective, randomized, open‐label, blinded endpoint design, and the primary endpoint was the incidence of major bleeding events (MBEs). Patients were randomized to uninterrupted dabigatran 150 mg twice daily or warfarin. In this study, we analyzed the results in Japanese patients. RESULTS: Of 704 enrolled patients in the study, 112 Japanese patients were randomized to dabigatran (n = 65) or warfarin (n = 47). MBEs were experienced by two patients: one in the dabigatran group (1.6%, cardiac tamponade) and one in the warfarin group (2.2%, groin hematoma) (risk difference vs warfarin −0.6%; 95% CI −5.8, 4.7). Within the Japanese subgroup, there were no thromboembolic events in both groups. CONCLUSION: While not designed to show statistical difference between two treatment groups, our results from the Japanese subgroup supported those from the overall population. Furthermore, this study provided clinical information regarding MBE, especially cardiac tamponade, in Japanese patients. John Wiley and Sons Inc. 2018-01-13 /pmc/articles/PMC5891433/ /pubmed/29657590 http://dx.doi.org/10.1002/joa3.12024 Text en © 2018 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Yoshida, Yukihiko Watarai, Masato Fujii, Kenshi Shimizu, Wataru Satomi, Kazuhiro Inden, Yasuya Murakami, Yoshimasa Murakami, Masato Iwasa, Atsushi Kimura, Masaomi Yamada, Nobuko Nakagawa, Tomofumi Nordaby, Matias Okumura, Ken Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial |
title | Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial |
title_full | Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial |
title_fullStr | Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial |
title_full_unstemmed | Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial |
title_short | Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial |
title_sort | comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: results of the japanese subgroup of the re‐circuit trial |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891433/ https://www.ncbi.nlm.nih.gov/pubmed/29657590 http://dx.doi.org/10.1002/joa3.12024 |
work_keys_str_mv | AT yoshidayukihiko comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT wataraimasato comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT fujiikenshi comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT shimizuwataru comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT satomikazuhiro comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT indenyasuya comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT murakamiyoshimasa comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT murakamimasato comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT iwasaatsushi comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT kimuramasaomi comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT yamadanobuko comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT nakagawatomofumi comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT nordabymatias comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT okumuraken comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial |